Journal of Medical Diagnostic Methods
Open Access

Nuclear Medicine: A Powerful Tool in Modern Diagnostics and Treatment

Gregory Tima^{* *}Correspondence: Gregory Tima, Department of Nuclear Medicine, Tsinghua University, Beijing, China, Email:

Author info »

Description

Nuclear medicine is a specialized area of medical science that uses small amounts of radioactive materials to diagnose, monitor, and treat a variety of diseases. Unlike conventional imaging techniques such as X-rays or Computed Tomography (CT) scans, which capture structural images of the body, nuclear medicine focuses on the physiological processes at the molecular level. This approach provides unique insights into how organs and tissues are functioning, making it an invaluable tool in both diagnostic and therapeutic settings [1]. At its core, nuclear medicine involves the use of radiopharmaceuticals radioactive compounds that are either injected, ingested, or inhaled by patients. These compounds emit gamma rays or other forms of radiation, which can be detected by special imaging devices such as gamma cameras or Positron Emission Tomography (PET) scanners. The radiopharmaceuticals typically consist of a radioactive isotope linked to a substance that targets specific organs or tissues in the body, allowing for both imaging and treatment [2-4]. The ability to observe functional processes such as blood flow, metabolism, or receptor activity within organs offers critical information that cannot be obtained through traditional imaging methods. This makes nuclear medicine particularly effective for detecting diseases in their earliest stages, assessing the effectiveness of treatments, and providing guidance for surgery or other interventions [5,6]. Nuclear medicine has a broad range of applications across various medical disciplines, particularly in the fields of oncology, cardiology, neurology, and endocrinology. Some of the most common uses include. Nuclear medicine plays a critical role in the diagnosis, staging, and monitoring of cancer. One of the most widely used imaging techniques in oncology is Positron Emission Tomography (PET). PET scans involve the use of a radiopharmaceutical called Fluorodeoxyglucose (FDG), a glucose analog that is preferentially taken up by cancer cells due to their higher metabolic activity [7]. FDG-PET scans allow clinicians to detect tumors, assess tumour activity, and monitor how well a tumour is responding to treatment. Nuclear medicine is also used for radionuclide therapy, in which radioactive substances are directly delivered to cancer cells to destroy them. This approach is commonly used for treating cancers like thyroid cancer, where radioactive iodine is administered to target and destroy thyroid cancer cells. In cardiology, nuclear medicine is important for evaluating heart function and detecting conditions such as Coronary Artery Disease (CAD) or myocardial infarction (heart attack). A common nuclear test used in cardiology is Myocardial Perfusion Imaging (MPI), which evaluates blood flow to the heart muscle [8,9]. A radiopharmaceutical is injected into the bloodstream, and imaging techniques track how well the heart muscle receives blood. MPI can reveal areas of reduced blood flow, which may indicate blockages or areas of heart muscle damage. Nuclear medicine also has applications in neurology, particularly for evaluating brain function [10]. One of the most well-known techniques is the PET scan, which can be used to assess brain activity and detect abnormalities in neurodegenerative diseases such as Alzheimer's, Parkinson’s, or epilepsy. For instance, a PET scan can identify cancerous tumours long before they become large enough to be detected by conventional imaging methods. Nuclear medicine also offers the potential for targeted therapy, where radioactive isotopes are delivered directly to diseased tissues, such as cancer cells. This method minimizes damage to surrounding healthy tissue and can improve the effectiveness of treatment while reducing side effects [11]. In addition, because radiopharmaceuticals are radioactive, they have a limited shelf life and must be handled carefully. However, stringent safety protocols are followed to ensure that patients and healthcare providers are not exposed to harmful radiation [12].

References

1. Cerudelli E, Gazzilli M, Bertoli M, Bertagna F, Giubbini R. Erdheim-Chester disease: The power of nuclear medicine imaging. Rev Esp Med Nucl Imagen Mol. 2020 ;39(5):323-324.

   [Crossref] [Google Scholar] [PubMed]

2. Fahey FH, Bom HH, Chiti A, Choi YY, Huang G, Lassmann M, et al. Standardization of administered activities in pediatric nuclear medicine: a report of the first nuclear medicine global initiative project, part 1statement of the issue and a review of available resources. J Nucl Med. 2015;56(4):646-651.

   [Crossref] [Google Scholar] [PubMed]

3. Weber S, Block A, Bärenfänger F. Assessment of attenuation properties for SLA and SLS 3D-printing materials in X-ray imaging and nuclear medicine. Z Med Phys. 2024.

   [Crossref] [Google Scholar] [PubMed]

4. Yu R, Gardner L, Ells Z, Dahlbom M, Salavati A, Bahri S, et al. Swelling of the Right Arm During a Nuclear Medicine Therapy for Metastatic Pheochromocytoma. AACE Clin Case Rep. 2024.

   [Google Scholar]

5. Belliveau GC. Leading into the future: Revising nuclear medicine education across Canada to satisfy the newly imposed CAMRT leadership competency. J Med Imaging Radiat Sci. 2021;52(4):32-38.

   [Crossref] [Google Scholar] [PubMed]

6. Signoriello M, Fornasier MR,  Denaro MD, Arfelli F, Santoro B, Severgnini M, et al. Assessment of total annual effective doses to representative person, for authorised and accidental releases from the Nuclear Medicine Department at Cattinara Hospital (Trieste, Italy). Phys Med. 2022;102:88-95.

   [Crossref] [Google Scholar] [PubMed]

7. Guleria M, Pallavi KJ, Gujarathi PP, Das T. Evaluation of acute intravenous toxicity of HEPES: Is Good's buffer good and safe enough for clinical utilization in nuclear medicine?. Nucl Med Biol. 2024;132.

   [Crossref] [Google Scholar] [PubMed]

8. Leung E. Radioisotope Therapy of Bone Metastases-A Nuclear Medicine Perspective. J Med Imaging Radiat Sci. 2019;50(4S1):34-35.

   [Crossref] [Google Scholar] [PubMed]

9. Graham MM, Delbeke D, Jadvar H. Point: the existential threat to nuclear medicine. J Am Coll Radiol. 2018;15(3):384-386.

   [Crossref] [Google Scholar] [PubMed]

10. Guiberteau MJ, Oates ME. Counterpoint: nuclear medicine’s decline: radiology is the solution, not the problem. J Am Coll Radiol. 2018;15(3):387-389.

    [Crossref] [Google Scholar] [PubMed]

11. Fahey FH, Grogg K,  Fakhri GE. Use of Monte Carlo techniques in nuclear medicine. J Am Coll Radiol. 2018;15(3):446-8.

    [Crossref] [Google Scholar] [PubMed]

12. Seibert JA, Morin RL. Patient Dose Monitoring and Focus on Nuclear Medicine Imaging Examinations. J Am Coll Radiol. 2018;15(1):88-89.

    [Crossref] [Google Scholar] [PubMed]